AHRQ Comparative Research Should Focus On Diseases, Not Drug Classes, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcomes research priority should be treatment options for diseases with a high prevalence among Medicare and Medicaid beneficiaries, PhRMA says. Payor comments specify therapeutic classes where comparative data is needed most.